Four year follow-up of trastuzumab plus adjuvant chemotherpy for operable HER2 positive breast cancer: Joint analysis of NNCTG N9831 and NSABP B-31. J Clin Oncol published online before print July 18, 2011
Wan, Y. (summary)
http://www.nelm.nhs.uk/en/NeLM-Area/News/2011---July/19/Four-year-follow-up-of-trastuzumab-plus-adjuvant-chemotherapy-for-operable-HER2-positive-breast-cancer-Joint-analysis-of-NCCTG-N9831-and-NSABP-B-31/
Four large trials evaluating adjuvant trastuzumab for HER2-positive breast cancer demonstrated significant improvements in disease-free survival (DFS; 36% to 52% reduction in DFS events) and overall survival (OS; 33% to 37% reduction in deaths). These data has led adjuvant trastuzumab becoming the foundation of care for HER2-positive early breast cancer.
